EUVIMEDEUVIMED entdecken
Open Access

Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying bla OXA-48

Maria F Mojica iD, Elise T Zeiser, Scott A Becka, David A Six iD, Greg Moeck iD, Robert A Bonomo iD, Krisztina M Papp-Wallace iD

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.03148-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Maria F Mojica und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents, beta-Lactamases, Enterobacteriaceae. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, ODCDC CDC HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ledaborbactam is a novel boronic-acid inhibitor of class A, C, and D β-lactamases, including OXA-48, being developed in combination with ceftibuten. Herein, we examined the in vitro activity of this combination vs. other orally bioavailable compounds against 50 Enterobacterales-carrying bla OXA-48 . Ranked by MIC 90 , ceftibuten-ledaborbactam was the most active (0.5 mg/L), followed by levofloxacin and tebipenem (8 mg/L), sulopenem (16 mg/L), and ceftibuten-clavulanic acid, ceftibuten and amoxicillin-clavulanic acid (≥32 mg/L). IMPORTANCE Carbapenemase-producing Enterobacterales (CPE) that produce class D OXA-48-like carbapenemases are among the most challenging pathogens to treat. Therefore, new compounds with in vitro activity against these bacteria are crucial due to the limited options available. In this study, we compared the in vitro antimicrobial activity of ceftibuten-ledaborbactam with that of other oral antibiotics, including tebipenem, sulopenem, ceftibuten-clavulanic acid, amoxicillin-clavulanic acid, and levofloxacin, against OXA-48-producing Enterobacterales. Our results show that ceftibuten-ledaborbactam has the most potent activity, with an MIC 90 of 0.5 mg/L.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesEnterobacteriaceaeCeftibutenMicrobial Sensitivity TestsHumansEnterobacteriaceae InfectionsBacterial ProteinsAdministration, Oralbeta-LactamsDrug Combinations

Stichwörter der Autor:innen

Ceftibuten-ledaborbactamEnterobacteralesOXA-48carbapenemaseβ-lactamβ-lactamase inhibitorβ-lactamases

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesCeftibutenBacterial Proteinsbeta-LactamsDrug Combinations

Autor:innen und Institutionen

  • Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA.
  • Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
  • CASE-VA Center for Antimicrobial Resistance and Epidemiology, Cleveland, Ohio, USA.
  • Venatorx Pharmaceuticals Inc., Malvern, Pennsylvania, USA.
  • Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.

ORCID-Profile: Maria F Mojica, David A Six, Greg Moeck, Robert A Bonomo, Krisztina M Papp-Wallace

Förderung

  • National Institute of Allergy and Infectious Diseases
  • ODCDC CDC HHS
  • NIAID NIH HHS
  • U.S. Department of Veterans Affairs
  • NIH HHS
  • BLRD VA
  • U.S. Department of Health and Human Services

Zitieren

APA

Mojica, M. F., Zeiser, E. T., Becka, S. A., Six, D. A., Moeck, G., Bonomo, R. A., & Papp-Wallace, K. M. (2026). Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying bla OXA-48. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03148-25

Vancouver

Mojica MF, Zeiser ET, Becka SA, Six DA, Moeck G, Bonomo RA, et al. Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying bla OXA-48. Microbiology Spectrum. 2026. doi:10.1128/spectrum.03148-25

BibTeX
@article{Mojica2026,
  author = {Mojica, Maria F and Zeiser, Elise T and Becka, Scott A and Six, David A and Moeck, Greg and Bonomo, Robert A and Papp-Wallace, Krisztina M},
  title = {Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying bla OXA-48},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.03148-25}
}
Kostenlos starten →